These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 31720351)

  • 1. Two cases of disseminated tuberculosis after negative screening before adalimumab treatment for immune-mediated inflammatory diseases.
    Cortez de Almeida RF; Cortez Cardoso Penha R; do Nascimento Barbosa L
    JAAD Case Rep; 2019 Nov; 5(11):1002-1005. PubMed ID: 31720351
    [No Abstract]   [Full Text] [Related]  

  • 2. Disseminated tuberculosis following negative QuantiFERON-TB gold tests during infliximab therapy: Implications for screening of hidradenitis suppurativa.
    Ntiri M; Haskin A; Lowenstein EJ
    JAAD Case Rep; 2022 Nov; 29():76-79. PubMed ID: 36199671
    [No Abstract]   [Full Text] [Related]  

  • 3. Tuberculosis screening prior to anti-tumor necrosis factor therapy among patients with immune-mediated inflammatory diseases in Japan: a longitudinal study using a large-scale health insurance claims database.
    Tomio J; Yamana H; Matsui H; Yamashita H; Yoshiyama T; Yasunaga H
    Int J Rheum Dis; 2017 Nov; 20(11):1674-1683. PubMed ID: 29076252
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Retesting for latent tuberculosis in patients with inflammatory bowel disease treated with TNF-α inhibitors.
    Papay P; Primas C; Eser A; Novacek G; Winkler S; Frantal S; Angelberger S; Mikulits A; Dejaco C; Kazemi-Shirazi L; Vogelsang H; Reinisch W
    Aliment Pharmacol Ther; 2012 Nov; 36(9):858-65. PubMed ID: 22978645
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Latent tuberculosis infection detection and active tuberculosis prevention in patients receiving anti-TNF therapy: an Italian nationwide survey.
    Cantini F; Lubrano E; Marchesoni A; Mathieu A; Olivieri I; Salvarani C; Scarpa R; Spadaro A
    Int J Rheum Dis; 2016 Aug; 19(8):799-805. PubMed ID: 26172207
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Paradoxical response with increased tumor necrosis factor-α levels to anti-tuberculosis treatment in a patient with disseminated tuberculosis.
    Watanabe S; Kaneko Y; Kawamoto H; Maehara T; Baba Y; Fujisaki I; Saito N; Ryu K; Seki A; Horikiri T; Kinoshita A; Takeda H; Saito K; Kuwano K
    Respir Med Case Rep; 2017; 20():201-204. PubMed ID: 28331797
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interferon-γ release assay versus tuberculin skin test prior to treatment with golimumab, a human anti-tumor necrosis factor antibody, in patients with rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis.
    Hsia EC; Schluger N; Cush JJ; Chaisson RE; Matteson EL; Xu S; Beutler A; Doyle MK; Hsu B; Rahman MU
    Arthritis Rheum; 2012 Jul; 64(7):2068-77. PubMed ID: 22238071
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Update of the guidelines of the Israeli Association of Rheumatology for the prevention of tuberculosis in patients treated with TNF-alpha blockers].
    Balbir-Gurman A; Lidgi M; Elkayam O
    Harefuah; 2014 Jun; 153(6):359-61, 366. PubMed ID: 25095612
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factors impacting the results of interferon-γ release assay and tuberculin skin test in routine screening for latent tuberculosis in patients with inflammatory bowel diseases.
    Papay P; Eser A; Winkler S; Frantal S; Primas C; Miehsler W; Novacek G; Vogelsang H; Dejaco C; Reinisch W
    Inflamm Bowel Dis; 2011 Jan; 17(1):84-90. PubMed ID: 20722065
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of the combination of a whole-blood interferon-gamma assay and the tuberculin skin test in detecting latent tuberculosis infection in rheumatoid arthritis patients receiving adalimumab therapy.
    Chen DY; Shen GH; Hsieh TY; Hsieh CW; Lan JL
    Arthritis Rheum; 2008 Jun; 59(6):800-6. PubMed ID: 18512714
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Contribution of a heparin-binding haemagglutinin interferon-gamma release assay to the detection of Mycobacterium tuberculosis infection in HIV-infected patients: comparison with the tuberculin skin test and the QuantiFERON-TB Gold In-tube.
    Wyndham-Thomas C; Dirix V; Schepers K; Martin C; Hildebrand M; Goffard JC; Domont F; Libin M; Loyens M; Locht C; Van Vooren JP; Mascart F
    BMC Infect Dis; 2015 Feb; 15():59. PubMed ID: 25886172
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Positive conversion of tuberculin skin test and performance of interferon release assay to detect hidden tuberculosis infection during anti-tumor necrosis factor agent trial.
    Park JH; Seo GY; Lee JS; Kim TH; Yoo DH
    J Rheumatol; 2009 Oct; 36(10):2158-63. PubMed ID: 19723901
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interferon-γ release assay for tuberculosis in patients with psoriasis treated with tumour necrosis factor antagonists: in vivo and in vitro analysis.
    Sauzullo I; Mengoni F; Marocco R; Potenza C; Skroza N; Tieghi T; Lichtner M; Vullo V; Mastroianni CM
    Br J Dermatol; 2013 Nov; 169(5):1133-40. PubMed ID: 23909256
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Follow-up of 1887 patients receiving tumor necrosis-alpha antagonists: Tuberculin skin test conversion and tuberculosis risk.
    Cagatay T; Bingol Z; Kıyan E; Yegin Z; Okumus G; Arseven O; Erkan F; Gulbaran Z; Erelel M; Ece T; Cagatay P; Kılıçaslan Z
    Clin Respir J; 2018 Apr; 12(4):1668-1675. PubMed ID: 29028148
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluating the use of the interferon-γ response to Mycobacterium tuberculosis-specific antigens in patients with psoriasis prior to antitumour necrosis factor-α therapy: a prospective head-to-head cross-sectional study.
    Martyn-Simmons CL; Mee JB; Kirkham BW; Groves RW; Milburn HJ
    Br J Dermatol; 2013 May; 168(5):1012-8. PubMed ID: 23278714
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disseminated Tuberculosis in a Psoriasis Patient under Adalimumab Treatment despite the Chemoprophylaxis of Latent Tuberculosis: A Case Report.
    Oh JH; Ham SP; Park HJ
    Ann Dermatol; 2021 Feb; 33(1):77-81. PubMed ID: 33911816
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biologic Agents and Tuberculosis.
    Dobler CC
    Microbiol Spectr; 2016 Dec; 4(6):. PubMed ID: 28084208
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of replacing tuberculin skin test with ex vivo interferon γ release assays on decision to administer prophylactic antituberculosis antibiotics before anti-TNF therapy.
    Mariette X; Baron G; Tubach F; Lioté F; Combe B; Miceli-Richard C; Flipo RM; Goupille P; Allez M; Salmon D; Emilie D; Carcelain G; Ravaud P
    Ann Rheum Dis; 2012 Nov; 71(11):1783-90. PubMed ID: 22258485
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tuberculosis screening in Portuguese healthcare workers using the tuberculin skin test and the interferon-gamma release assay.
    Torres Costa J; Sá R; Cardoso MJ; Silva R; Ferreira J; Ribeiro C; Miranda M; Plácido JL; Nienhaus A
    Eur Respir J; 2009 Dec; 34(6):1423-8. PubMed ID: 19948911
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detecting latent tuberculosis infection during anti-tumor necrosis factor therapy.
    Ringrose JS; Sanche SE; Taylor-Gjevre RM
    Clin Exp Rheumatol; 2011; 29(5):790-4. PubMed ID: 21961892
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.